Cancer Biomarkers in Body Fluids: Biomarkers in Circulation
Autor Gabriel D. Dakuboen Limba Engleză Hardback – 15 dec 2016
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (2) | 1095.36 lei 6-8 săpt. | |
Springer International Publishing – 8 iun 2018 | 1095.36 lei 6-8 săpt. | |
Springer International Publishing – 4 iul 2018 | 1422.50 lei 6-8 săpt. | |
Hardback (3) | 1099.35 lei 3-5 săpt. | |
Springer International Publishing – 26 sep 2019 | 1099.35 lei 3-5 săpt. | |
Springer International Publishing – 9 sep 2016 | 1102.31 lei 6-8 săpt. | |
Springer International Publishing – 15 dec 2016 | 1429.80 lei 6-8 săpt. |
Preț: 1429.80 lei
Preț vechi: 1505.05 lei
-5% Nou
Puncte Express: 2145
Preț estimativ în valută:
273.62€ • 283.93$ • 228.70£
273.62€ • 283.93$ • 228.70£
Carte tipărită la comandă
Livrare economică 17-31 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319483597
ISBN-10: 3319483595
Pagini: 480
Ilustrații: XIX, 509 p. 20 illus. in color.
Dimensiuni: 155 x 235 x 29 mm
Greutate: 0.92 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319483595
Pagini: 480
Ilustrații: XIX, 509 p. 20 illus. in color.
Dimensiuni: 155 x 235 x 29 mm
Greutate: 0.92 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
1. Melanoma Biomarkers in Circulation. - 2. Head and Neck Cancer Biomarkers in Circulation. - 3. Lung Cancer Biomarkers in Circulation. - 4. Breast Cancer Biomarkers in Circulation. - 5. Esophageal Cancer Biomarkers in Circulation. - 6. Gastric Cancer Biomarkers in Circulation. - 7. Colorectal Cancer Biomarkers in Circulation. - 8. Hepatocellular Carcinoma Biomarkers in Circulation. - 9. Pancreatic Cancer Biomarkers in Circulation. - 10. Renal Cell Carcinoma Biomarkers in Circulation. - 11. Urothelial Bladder Cancer Biomarkers in Circulation. - 12. Prostate Cancer Biomarkers in Circulation. - 13. Ovarian Cancer Biomarkers in Circulation. - 14. Endometriosis Biomarkers in Body Fluids. - 15. Endometrial Cancer Biomarkers in Circulation. - 16. Cervical Cancer Biomarkers in Circulation. - 17. Endocrine Cancer Biomarkers in Circulation. - 18. Brain Tumor Biomarkers in Circulation.
Notă biografică
Dr. Gabriel D. Dakubo is an Assistant Professor of Molecular Medicine and Human Anatomy in the Division of Medical Sciences at the Northern Ontario School of Medicine. He received his BSc and MBChB degrees from the University of Ghana, followed by the pursuance of a Postdoctoral research fellowship in Molecular Medicine at the Ottawa Hospital Research Institute, Canada. Dr. Dakubo’s passion is in noninvasive deployment of biomarkers for cancer management. While an expert in mitochondrial genetic alterations in cancer, he also has a keen interest in the inter-genomic communications that occur in the cancer cell, as well as the Slaughter’s concept of field cancerization. Dr. Dakubo is well published, and is a reviewer of a number of esteemed journals, including Clinical Cancer Research.
Textul de pe ultima copertă
This book examines in depth the evidence, clinical applications and potential cancer signatures in the circulation and discusses alterations in circulating cell-free nucleic acids, and circulating tumor DNA, as well as the epigenome, genome, transcriptome (coding and noncoding), proteome (both traditional serum proteins and proteomic profiles) and metabolome. Further, it highlights the clinical applications of circulating tumor cells for each cancer type and addresses the emerging importance of extracellular vesicular contents, including miRNA, oncogenes and drug resistant factors. As such, it offers a valuable reference guide for cancer researchers, oncologists, clinicians, surgeons, medical students, oncology nurses, diagnostic laboratories, and the pharmaceutical industry.
Caracteristici
Presents cancer biomarkers for noninvasive diagnosis of 18 different body fluids
Shows prosprectives for a coordinated validation of cancer biomarkers by industries, regulatory bodies, and academics for clinical translation
Presents opportunities for cancer personalized medicine ?
Shows prosprectives for a coordinated validation of cancer biomarkers by industries, regulatory bodies, and academics for clinical translation
Presents opportunities for cancer personalized medicine ?